Efficacy of LUMIGAN (bimatoprost ophthalmic solution)



	Efficacy
	Beta Blockers Combination / Dual Therapy Latanoprost Travoprost African American Populations Cost Effectiveness
	Your Patients
	Tools and Resources
	Safety & Pharmacology
	Prescribing Information

Home

References

Newsroom

Home > Efficacy

LUMIGAN produces lowest mean IOP
Proven in multiple published, peer-reviewed studies

Author	Study	Lowest mean IOP	Mean IOP at study
Bournias* ¹	vs latanoprost (replacement)	LUMIGAN (n = 1283)	17.0 mm Hg (time points not standardized)
Cantor ²	vs travoprost (n = 12)	LUMIGAN (n = 14)	15.2 mm Hg ( 9 AM )
Cohen ³	vs timolol (n = 81)	LUMIGAN (n = 167)	17.2 mm Hg ( 10 AM )
Coleman ⁴	vs timolol/dorzolamide (n = 87)	LUMIGAN (n = 90)	17.1 mm Hg ( 10 AM )
DuBiner ⁵	vs latanoprost (n = 22)	LUMIGAN (n = 21)	17.6 mm Hg? ( 8 AM )
Gandolfi ⁶	vs latanoprost (n = 113)	LUMIGAN (n = 119)	17.5 mm Hg ( 8 AM )
Higginbotham ⁷	vs timolol (n = 241)	LUMIGAN (n = 474)	17.0 mm Hg ( 10 AM )
Lee* ⁸	vs beta-blocker replacement and latanoprost replacement	LUMIGAN (n = 1161)	16.7 mm Hg(time points not standardized)
Mundorf ⁹	vs travoprost (n = 27)	LUMIGAN (n = 24)	17.3 mm Hg ( 10 AM )
Noecker ¹⁰	vs latanoprost (n = 136)	LUMIGAN (n = 133)	17.4 mm Hg ( 8 AM )
Parrish ¹¹	vs latanoprost (n = 136) and travoprost (n = 138)	LUMIGAN (n = 137)	17.0 mm Hg ( 8 AM )
Walters ¹²	vs latanoprost (n = 38) and timolol (n = 39)	LUMIGAN (n = 38)	14.6 mm Hg ( 8 AM )

*Open-label, unmasked trial. ? Hand-calculated, based on baseline and mean change from baseline at study conclusion. Study durations ranged from 1-12 months. LUMIGAN consistently achieved lowest mean IOP; difference was not always statistically significant.

Maximize your patient's outcome with LUMIGAN therapy

LUMIGAN (bimatoprost ophthalmic solution) 0.03% is for the treatment of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.

Important Safety Information
LUMIGAN (bimatoprost ophthalmic solution) 0.03% has been reported to cause darkening (pigmentation) of eye color, eyelid skin and eyelashes, as well as increased growth of eyelashes. Pigmentation changes can increase as long as LUMIGAN is used. After stopping LUMIGAN, darkening of eye color is likely to be permanent while darkening of the eyelid skin and eyelash changes may be reversible. The effects of increased darkening beyond 5 years are not known.

The most common side effects are eye redness, growth of eyelashes, and itchy eyes.